PUBLIC COMPANY
save$TSHATaysha Gene Therapies, Inc.
$TSHA5.9900-6.48%Dallas, TX, USupdated 10h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
- phase3A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)
- phase2Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 10, 26SELLNagendran Sukumar· President and Head of R&D−$892K↗
routine RSU / option mechanics (2)
- Apr 10, 26option exerciseNagendran Sukumar · President and Head of R&D19,021 sh
- Apr 10, 26option exerciseNagendran Sukumar · President and Head of R&D19,021 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 14m ago
Found something off?
comments(0)
5-min edit window · permanent after that